The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 17, 2026 for Espee Therapeutics LLP
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Espee Therapeutics LLP, part of the promoter group of Senores Pharmaceuticals, has created a pledge on 4,00,000 (four lakh) equity shares of the company. The disclosure was filed with BSE and NSE on February 17, 2026, under Regulation 31(1) and 31(2) of SEBI's Substantial Acquisition of Shares & Takeovers Regulations, 2011. The company has submitted the disclosure received from the promoter group entity to both stock exchanges. No details on the pledgee (lender) or the purpose of the pledge have been disclosed in this filing.
Promoter share pledging is generally viewed as a mild negative signal by investors, as it can indicate the promoter is raising debt against holdings. However, with only 4 lakh shares pledged, the materiality depends on the size relative to total promoter holding and total share capital — investors should watch for further disclosures to gauge significance.